Division of Vascular and Endovascular Surgery, Beth Israel Deaconess Medical Center, Boston, Mass.
Division of Vascular and Endovascular Surgery, Mayo Clinic, Rochester, Minn.
J Vasc Surg. 2019 Mar;69(3):728-737. doi: 10.1016/j.jvs.2018.06.205. Epub 2018 Oct 6.
Endovascular aneurysm repair (EVAR) has decreased the perioperative mortality for patients undergoing abdominal aortic aneurysm repair and has increased the rates of elective aneurysm repair in the elderly. However, Medicare will not cover abdominal aortic aneurysm screening for beneficiaries over 75 years of age. Consequently, abdominal aortic aneurysm treatment in this population depends on incidental detection. Targeted coverage for screening in this population, however, might be beneficial for a subgroup of patients.
To identify a subset of elderly patients who would potentially benefit from an expanded screening policy, we reviewed all patients greater than 75 years old undergoing elective EVAR in the Vascular Quality Initiative between 2003 and 2016. We used Cox regression with multivariable fractional polynomials to construct a risk model for 5-year survival in elderly patients to identify a subpopulation who might benefit the most from screening and performed internal validation using the bootstrapping technique.
We identified 10,676 patients greater than 75 years old undergoing elective EVAR. Although perioperative mortality varied with age, it was only 2.1% in the oldest group of patients (>85 years). Significant predictors included in our final risk model for 5-year survival in the elderly included age, aortic diameter, hemoglobin, current smoking, white race, body mass index, renal function, congestive heart failure, statin use, chronic obstructive pulmonary disease, and ejection fraction. The risk model produced risk scores ranging from a possible -2 to 33. The mean and median risk score were 6.9 and 6.0, respectively, with a right skew. We categorized the risk scores into four groups: -2 to 4 points, 5-8 points, 9-13 points, and more than 13 points, with associated 5-year survivals of 88%, 79%, 68%, and 49%, respectively. The model showed adequate discrimination and calibration, with a C-statistic of 0.69 and a calibration score of 0.99 (predicted 5-year survival of 0.78 compared with an observed 5-year survival of 0.77) and a Brier score of 0.15. Internal validation demonstrated an optimism-corrected C-statistic of 0.69 and a calibration slope of 1.0.
Elective EVAR in elderly patients chosen to undergo repair is associated with acceptable perioperative mortality. Our risk score can be used to define optimal patients for expanded screening into all but the highest risk group based on expected postoperative 5-year survival to justify removing this Medicare coverage restriction.
血管内动脉瘤修复术(EVAR)降低了接受腹主动脉瘤修复术患者的围手术期死亡率,并增加了老年患者择期动脉瘤修复术的比例。然而,医疗保险不为 75 岁以上的受益人提供腹主动脉瘤筛查。因此,该人群的腹主动脉瘤治疗取决于偶然发现。然而,针对该人群的筛查的有针对性的覆盖可能对一部分患者有益。
为了确定一组可能从扩大筛查政策中受益的老年患者亚组,我们回顾了 2003 年至 2016 年间血管质量倡议中所有接受择期 EVAR 的 75 岁以上患者。我们使用 Cox 回归和多变量分数多项式构建了一个用于确定老年患者 5 年生存率的风险模型,以确定最有可能从筛查中受益的亚组,并使用自举技术进行内部验证。
我们确定了 10676 名 75 岁以上接受择期 EVAR 的患者。尽管围手术期死亡率随年龄变化,但在最年长的患者组(>85 岁)仅为 2.1%。我们最终的老年患者 5 年生存率风险模型中的重要预测因素包括年龄、主动脉直径、血红蛋白、当前吸烟状况、白种人、体重指数、肾功能、充血性心力衰竭、他汀类药物使用、慢性阻塞性肺疾病和射血分数。该风险模型产生的风险评分范围从可能的-2 到 33。平均和中位数风险评分分别为 6.9 和 6.0,呈右偏态。我们将风险评分分为四组:-2 至 4 分、5-8 分、9-13 分和 13 分以上,分别对应的 5 年生存率为 88%、79%、68%和 49%。该模型具有较好的区分度和校准度,C 统计量为 0.69,校准评分 0.99(预测的 5 年生存率为 0.78,而观察到的 5 年生存率为 0.77),Brier 评分 0.15。内部验证显示校正后的 C 统计量为 0.69,校准斜率为 1.0。
选择进行修复的老年患者接受择期 EVAR 与可接受的围手术期死亡率相关。我们的风险评分可用于根据预期术后 5 年生存率来确定最合适的患者进行扩大筛查,除了风险最高的患者组之外,都可以以此来证明取消这一医疗保险限制是合理的。